Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

The Lancet Oncology

Volumn 17, Issue 11, 2016, Pages 1521-1532

  Baumert, Brigitta G ^a,b   Hegi, Monika E ^c   van den Bent, Martin J ^d   von Deimling, Andreas ^e   Gorlia, Thierry ^f   Hoang Xuan, Khê ^g   Brandes, Alba A ^h   Kantor, Guy ⁱ   Taphoorn, Martin J B ^j,k   Hassel, Mohamed Ben ^l   Hartmann, Christian ^e,m   Ryan, Gail ⁿ   Capper, David ^e   Kros, Johan M ^d   Kurscheid, Sebastian ^c,o   Wick, Wolfgang ^e   Enting, Roelien ^p   Reni, Michele ^q   Thiessen, Brian ^r   Dhermain, Frederic ^s   Bromberg, Jacoline E ^d   Feuvret, Loic ^g   Reijneveld, Jaap C ^t   Chinot, Olivier ^u   Gijtenbeek, Johanna M M ^v   Rossiter, John P ^w   Dif, Nicolas ^f   Balana, Carmen ^x   Bravo Marques, Jose ^y   Clement, Paul M ^z   Marosi, Christine ^aa   Tzuk Shina, Tzahala ^ab   Nordal, Robert A ^ac   Rees, Jeremy ^ad   Lacombe, Denis ^f   Mason, Warren P ^ae   Stupp, Roger ^c,af   more..

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f EORTC DATA CENTER   (Belgium)

^g SORBONNE UNIVERSITÉ   (France)

^h IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

ⁱ INSTITUT BERGONIÉ   (France)

^j MEDICAL CENTER HAAGLANDEN   (Netherlands)

^k LEIDEN UNIVERSITY   (Netherlands)

^l CENTRE EUGÈNE MARQUIS   (France)

^m HANNOVER MEDICAL SCHOOL   (Germany)

ⁿ PETER MACCALLUM CANCER CENTRE   (Australia)

^o Australian National University   (Australia)

^p UNIVERSITY OF GRONINGEN   (Netherlands)

^q SAN RAFFAELE HOSPITAL   (Italy)

^r BRITISH COLUMBIA CANCER AGENCY   (Canada)

^s INSTITUT GUSTAVE ROUSSY   (France)

^t VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^u TIMONE HOSPITAL   (France)

^v RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^w QUEEN S UNIVERSITY   (Canada)

^x HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^y INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^z UNIVERSITY OF LEUVEN   (Belgium)

^aa MEDICAL UNIVERSITY OF VIENNA   (Austria)

^ab Rambam Health Care Campus   (Israel)

^ac UNIVERSITY OF CALGARY   (Canada)

^ad NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^ae UNIVERSITY OF TORONTO   (Canada)

^af UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ADULT; ALLERGY; ANEMIA; ARTICLE; ASTROCYTOMA; BLEEDING; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CAUSE OF DEATH; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; GENE DELETION; GENETIC ASSOCIATION; HEART DISEASE; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; INFECTION; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; LEUKOPENIA; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MGMT GENE; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OLIGODENDROGLIOMA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; SOMNOLENCE; STEREOTACTIC BIOPSY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR VOLUME; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VISUAL DISORDER; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFORMAL RADIOTHERAPY; GENETICS; GLIOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; RADIOTHERAPY, CONFORMAL;

EID: 84995596353     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30313-8     Document Type: Article

References (44)

1. 1 Soffietti, R, Baumert, BG, Bello, L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17 (2010), 1124–1133.
2. 2 Douw, L, Klein, M, Fagel, SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8 (2009), 810–818.
3. 3 Pignatti, F, van den Bent, M, Curran, D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20 (2002), 2076–2084.
4. 4 Jenkins, RB, Blair, H, Ballman, KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66 (2006), 9852–9861.
5. 5 Suzuki, H, Aoki, K, Chiba, K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47 (2015), 458–468.
6. 6 Karim, AB, Maat, B, Hatlevoll, R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36 (1996), 549–556.
7. 7 van den Bent, MJ, Afra, D, de Witte, O, et al., for the EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366 (2005), 985–990.
8. 8 Shaw, E, Arusell, R, Scheithauer, B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20 (2002), 2267–2276.
9. 9 Buckner, JC, Shaw, EG, Pugh, SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374 (2016), 1344–1355.
10. 10 Stupp, R, Gander, M, Leyvraz, S, Newlands, E, Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2 (2001), 552–560.
11. 11 Hoang-Xuan, K, Capelle, L, Kujas, M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22 (2004), 3133–3138.
12. 12 Quinn, JA, Reardon, DA, Friedman, AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21 (2003), 646–651.
13. 13 Brada, M, Vivers, L, Abson, C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14 (2003), 1715–1721.
14. 14 Ricard, D, Kaloshi, G, Amiel-Benouaich, A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61 (2007), 484–490.
15. 15 Tolcher, AW, Gerson, SL, Denis, L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 (2003), 1004–1011.
16. 16 Brandes, AA, Tosoni, A, Cavallo, G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95 (2006), 1155–1160.
17. 17 Wick, A, Felsberg, J, Steinbach, JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25 (2007), 3357–3361.
18. 18 Reijneveld, JC, Taphoorn, MJ, Coens, C, et al. Health-related quality of life in patients with high-risk low-grade glioma: a randomised, controlled, phase 3 trial. Lancet Oncol, 2016 published online Sept 26. http://dx.doi.org/10.1016/S1470-2045(16)30305-9.
19. 19 Kleihues, P, Cavenee, WK, Pathology and genetics of tumours of the nervous system, 2000, IARC Press, Lyon.
20. 20 Yan, H, Parsons, DW, Jin, G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (2009), 765–773.
21. 21 Weber, DC, Poortmans, PM, Hurkmans, CW, Aird, E, Gulyban, A, Fairchild, A, Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting. Radiother Oncol 100 (2011), 150–156.
22. 22 Musat, E, Roelofs, E, Bar-Deroma, R, et al. Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033–26033: first evaluation of quality of radiotherapy planning. Radiother Oncol 95 (2010), 218–224.
23. 23 Fairchild, A, Weber, DC, Bar-Deroma, R, et al. Quality assurance in the EORTC 22033–26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review. Radiother Oncol 103 (2012), 287–292.
24. 24 Hartmann, C, Mueller, W, Lass, U, Kamel-Reid, S, von Deimling, A, Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 64 (2005), 10–14.
25. 25 Seiz, M, Tuettenberg, J, Meyer, J, et al. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 120 (2010), 261–267.
26. 26 Reuss, DE, Sahm, F, Schrimpf, D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129 (2015), 133–146.
27. 27 Bady, P, Sciuscio, D, Diserens, AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124 (2012), 547–560.
28. 28 Bady, P, Delorenzi, M, Hegi, ME, Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors. J Mol Diagn 18 (2016), 350–361.
29. 29 Ceccarelli, M, Barthel, FP, Malta, TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164 (2016), 550–563.
30. 30 Wiestler, B, Capper, D, Sill, M, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 128 (2014), 561–571.
31. 31 Weller, M, Weber, RG, Willscher, E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129 (2015), 679–693.
32. 32 Louis, DN, Ohgaki, H, Wiestle, OD, Cavenee, WK, (eds.) WHO classification of tumours of the central nervous system, revised 4th edn., 2016, IARC, Lyon.
33. 33 Reuss, DE, Kratz, A, Sahm, F, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 129 (2015), 407–417.
34. 34 Reuss, DE, Mamatjan, Y, Schrimpf, D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129 (2015), 867–873.
35. 35 Turcan, S, Rohle, D, Goenka, A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483 (2012), 479–483.
36. 36 van den Bent, MJ, Erdem Eraslan, L, Idbaih, A, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res 19 (2013), 5513–5522.
37. 37 Wick, W, Meisner, C, Hentschel, B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81 (2013), 1515–1522.
38. 38 Boele, FW, Douw, L, Reijneveld, JC, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. J Clin Oncol 33 (2015), 1023–1029.
39. 39 Correa, DD, DeAngelis, LM, Shi, W, Thaler, HT, Lin, M, Abrey, LE, Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol 81 (2007), 175–184.
40. 40 Wick, W, Roth, P, Hartmann, C, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol, 2016, 10.1093/neuonc/now133 published online July 1.
41. 41 van den Bent, MJ, Brandes, AA, Taphoorn, MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31 (2013), 344–350.
42. 42 Cairncross, G, Wang, M, Shaw, E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31 (2013), 337–343.
43. 43 Pallud, J, Llitjos, JF, Dhermain, F, et al. Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol 14 (2012), 496–505.
44. 44 Cairncross, JG, Wang, M, Jenkins, RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32 (2014), 783–790.